Subgroup analysis of HCC suggests that in some clinicopathological states, such as in patients receiving sorafenib treatment or in patients with alcoholism or hepatitis virus infection, biopsy monitoring of RNF125 levels may benefit the prediction of RFS and OS and guide clinical treatment, but requires further clinical studies to demonstrate. Here, RNF125 is linked to hepatocellular carcinoma.